for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cadila Healthcare Ltd

CADI.NS

Latest Trade

409.70INR

Change

16.00(+4.06%)

Volume

19,640,911

Today's Range

395.05

 - 

423.00

52 Week Range

202.00

 - 

423.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
393.70
Open
395.05
Volume
19,640,911
3M AVG Volume
97.47
Today's High
423.00
Today's Low
395.05
52 Week High
423.00
52 Week Low
202.00
Shares Out (MIL)
1,023.74
Market Cap (MIL)
403,047.50
Forward P/E
23.52
Dividend (Yield %)
0.89

Next Event

Q2 2021 Cadila Healthcare Ltd Earnings Release

Latest Developments

More

Cadila Healthcare Gets Tentative U.S. FDA Nod For Empagliflozin And Linagliptin Tablets

Cadila Healthcare Gets Final Approval From FDA For Sevelamer Carbonate Tablets

India's Cadila Healthcare June-Qtr Consol Net Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cadila Healthcare Ltd

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Windlas Healthcare Pvt Ltd, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth Greencross Limited, among others.

Industry

Biotechnology & Drugs

Contact Info

Zydue Tower, Satellite Cross Road

380015

India

+91.79.26868100

http://zyduscadila.com/

Executive Leadership

Pankaj Ramanbhai Patel

Non-Executive Chairman of the Board

Nitin D. Parekh

Chief Financial Officer

Dhaval N. Soni

Company Secretary, Chief Compliance Officer

Sharvil P. Patel

Managing Director, Executive Director

Ganesh N. Nayak

Executive Director

Key Stats

2.67 mean rating - 33 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

119.0K

2019

131.7K

2020

142.5K

2021(E)

152.3K
EPS (INR)

2018

17.350

2019

18.060

2020

15.040

2021(E)

16.740
Price To Earnings (TTM)
30.41
Price To Sales (TTM)
2.80
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
19.83
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Cadila Healthcare Says Zydus Gets Approval To Study Desidustat In Management Of COVID-19

* ZYDUS RECEIVES APPROVAL FROM COFERIS, MEXICO TO STUDY DESIDUSTAT IN MANAGEMENT OF COVID-19 Source text for Eikon: Further company coverage:

India approves human trials for second COVID-19 vaccine candidate

Zydus has received approval from Indian regulators to begin human studies for its COVID-19 vaccine contender, the drugmaker said on Friday, as the novel coronavirus infections continue to surge in the world's fourth worst-hit nation.

BRIEF-Cadila Says Zydus' COVID-19 Vaccine Gets Nod To Start Human Clinical Trials

* ZYDUS' VACCINE FOR COVID-19 COMPLETES PRECLINICAL DEVELOPMENT, GETS NOD TO INITIATE HUMAN CLINICAL TRIALS

BRIEF-Cadila Healthcare Gets Final U.S. FDA Nod For Meclizine Hydrochloride Tablets

* ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR MECLIZINE HYDROCHLORIDE TABLETS Source text for Eikon: Further company coverage:

BRIEF-India's Cadila Healthcare March-Qtr Consol Net Profit Falls

* MARCH QUARTER CONSOL NET PROFIT 3.92 BILLION RUPEES VERSUS PROFIT OF 4.60 BILLION RUPEES YEAR AGO

BRIEF-Cadila Healthcare's Zydus Signs Non-Exclusive Pact With Gilead Sciences For Remdesivir

* ZYDUS SIGNS A NON EXCLUSIVE LICENSING AGREEMENT WITH GILEAD SCIENCES TO MANUFACTURE AND MARKET REMDESIVIR Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare's Zydus Cadila Gets Final U.S. FDA Nod For Atazanavir

* ZYDUS CADILA RECEIVES FINAL APPROVAL FROM USFDA FOR ATAZANAVIR CAPSULRES Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Says Baddi Unit Gets Establishment Inspection Report

* FORMULATIONS MANUFACTURING FACILITY AT BADDI, INDIA RECEIVED AN ESTABLISHMENT INSPECTION REPORT Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Unit Launches Prostate Cancer Drug Enzalutamide

* DRUG PRICED AT 5,995 RUPEES Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Gets Final U.S. FDA Nod For Deferasirox Tablets

* RECEIVES FINAL APPROVAL FROM USFDA FOR DEFERASIROX TABLETS FOR ORAL SUSPENSION Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Says Reports On Workers At Co's Plant Being COVID-19 Positive Are Factually Incorrect

* MEDIA REPORTS STATING THAT WORKERS AT CO'S PLANT WERE FOUND COVID-19 POSITIVE ARE FACTUALLY INCORRECT Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Signs Deal To Sell 49% Of Windlas Healthcare

* SIGNED AGREEMENT FOR SALE OF 49% OF WINDLAS HEALTHCARE PRIVATE LIMITED Source text for Eikon: Further company coverage:

BRIEF-Zydus Explores Biologicals Route To Treat Coronavirus With Interferon Alpha-2B

* CADILA HEALTHCARE LTD - ZYDUS EXPLORES BIOLOGICALS ROUTE TO TREAT NOVEL CORONAVIRUS WITH LONG-ACTING INTERFERON ALPHA-2B

BRIEF-Cadila Healthcare-Zydus Receives Final Approval From USFDA For Erlotinib Tablets

* CADILA HEALTHCARE LTD -ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR ERLOTINIB TABLETS Source text for Eikon: Further company coverage:

BRIEF-Cadila Approves Sale Of 2% Shares Of Unit Windlas Healthcare For 40.6 Mln Rupees

* APPROVED & SIGNED DEFINITIVE AGREEMENT FOR SALE OF 2% OF SHARE CAPITAL OF CO'S UNIT WINDLAS HEALTHCARE

BRIEF-Zydus Receives Tentative USFDA Approval For Macitentan Tablets

* ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR MACITENTAN TABLETS Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Ltd -Zydus Receives Tentative Approval From USFDA For Empagliflozin Tablets

* CADILA HEALTHCARE LTD -ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR EMPAGLIFLOZIN TABLETS Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Gets Final USFDA Nod For Imatinib Mesylate Tablets

* ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR IMATINIB MESYLATE TABLETS Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare Says Is Carrying Out Testing Of Coronavirus Vaccine On Animals

* TESTING OF CORONAVIRUS VACCINE BEING CARRIED OUT ON ANIMALS; HUMAN CLINICAL TRIALS TO FOLLOW AFTER SUCCESSFUL TEST RESULTS Source text for Eikon: Further company coverage:

BRIEF-Zydus Receives Final Approval From U.S. FDA For Perphenazine

* ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR PERPHENAZINE TABLETS USP Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up